A Mebazaa1,2,3, H Tolppanen4,5, C Mueller6, J Lassus5, S DiSomma7, G Baksyte8, M Cecconi9, D J Choi10, A Cohen Solal4,11,12, M Christ13, J Masip14, M Arrigo4, S Nouira15, D Ojji16, F Peacock17, M Richards18, N Sato19, K Sliwa20, J Spinar21, H Thiele22, M B Yilmaz23, J Januzzi24. 1. U 942 Inserm, Paris, France. alexandre.mebazaa@aphp.fr. 2. University Paris Diderot, Sorbonne Paris Cité, Paris, France. alexandre.mebazaa@aphp.fr. 3. Department of Anesthesia and Critical Care, Hôpital Lariboisière, APHP, Paris, France. alexandre.mebazaa@aphp.fr. 4. U 942 Inserm, Paris, France. 5. Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland. 6. Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, Basel, Switzerland. 7. Department of Medical Sciences and Translational Medicine, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy. 8. Department of Cardiology, Kaunas University of Medicine, Kaunas, Lithuania. 9. Anaesthesia and Intensive Care, St George's Hospital and Medical School, London, SW17 0QT, UK. 10. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. 11. University Paris Diderot, Sorbonne Paris Cité, Paris, France. 12. Department of Cardiology, Hôpital Lariboisiere, APHP, Paris, France. 13. Department of Emergency and Intensive Care Medicine, Paracelsus Medical University, Nuremberg, Germany. 14. Department of Intensive Care Medicine, Consorci Sanitari Integral, University of Barcelona, Barcelona, Spain. 15. Emergency Department and Research Unit UR06SP21, Fattouma Bourguiba University Hospital, Monastir, Tunisia. 16. Cardiology Unit, Department of Medicine, University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria. 17. Department of Emergency Medicine, Baylor College of Medicine, Boston, MA, USA. 18. Christchurch Cardioendocrine Research Group, Christchurch Hospital, Christchurch, New Zealand. 19. Internal Medicine, Cardiology, and Intensive Care Unit, Nippon Medical School Musashi-Kosugi Hospital, Kawasaki, Japan. 20. Faculty of Health Sciences, Hatter Institute for Cardiovascular Research in Africa and IIDMM, University of Cape Town, Cape Town, South Africa. 21. Department of Cardiovascular Disease, International Clinical Research Center, University Hospital Brno, Brno, Czech Republic. 22. Medical Clinic II (Cardiology/Angiology/Intensive Care Medicine), University Heart Centre Luebeck, University Hospital Schleswig-Holstein, Lübeck, Germany. 23. Department of Cardiology, Cumhuriyet University School of Medicine, Sivas, Turkey. 24. Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA.
Abstract
PURPOSE: Acute heart failure (AHF) causes high burden of mortality, morbidity, and repeated hospitalizations worldwide. This guidance paper describes the tailored treatment approaches of different clinical scenarios of AHF and CS, focusing on the needs of professionals working in intensive care settings. RESULTS: Tissue congestion and hypoperfusion are the two leading mechanisms of end-organ injury and dysfunction, which are associated with worse outcome in AHF. Diagnosis of AHF is based on clinical assessment, measurement of natriuretic peptides, and imaging modalities. Simultaneously, emphasis should be given in rapidly identifying the underlying trigger of AHF and assessing severity of AHF, as well as in recognizing end-organ injuries. Early initiation of effective treatment is associated with superior outcomes. Oxygen, diuretics, and vasodilators are the key therapies for the initial treatment of AHF. In case of respiratory distress, non-invasive ventilation with pressure support should be promptly started. In patients with severe forms of AHF with cardiogenic shock (CS), inotropes are recommended to achieve hemodynamic stability and restore tissue perfusion. In refractory CS, when hemodynamic stabilization is not achieved, the use of mechanical support with assist devices should be considered early, before the development of irreversible end-organ injuries. CONCLUSION: A multidisciplinary approach along the entire patient journey from pre-hospital care to hospital discharge is needed to ensure early recognition, risk stratification, and the benefit of available therapies. Medical management should be planned according to the underlying mechanisms of various clinical scenarios of AHF.
PURPOSE: Acute heart failure (AHF) causes high burden of mortality, morbidity, and repeated hospitalizations worldwide. This guidance paper describes the tailored treatment approaches of different clinical scenarios of AHF and CS, focusing on the needs of professionals working in intensive care settings. RESULTS: Tissue congestion and hypoperfusion are the two leading mechanisms of end-organ injury and dysfunction, which are associated with worse outcome in AHF. Diagnosis of AHF is based on clinical assessment, measurement of natriuretic peptides, and imaging modalities. Simultaneously, emphasis should be given in rapidly identifying the underlying trigger of AHF and assessing severity of AHF, as well as in recognizing end-organ injuries. Early initiation of effective treatment is associated with superior outcomes. Oxygen, diuretics, and vasodilators are the key therapies for the initial treatment of AHF. In case of respiratory distress, non-invasive ventilation with pressure support should be promptly started. In patients with severe forms of AHF with cardiogenic shock (CS), inotropes are recommended to achieve hemodynamic stability and restore tissue perfusion. In refractory CS, when hemodynamic stabilization is not achieved, the use of mechanical support with assist devices should be considered early, before the development of irreversible end-organ injuries. CONCLUSION: A multidisciplinary approach along the entire patient journey from pre-hospital care to hospital discharge is needed to ensure early recognition, risk stratification, and the benefit of available therapies. Medical management should be planned according to the underlying mechanisms of various clinical scenarios of AHF.
Authors: Veli-Pekka Harjola; Johan Lassus; Alessandro Sionis; Lars Køber; Tuukka Tarvasmäki; Jindrich Spinar; John Parissis; Marek Banaszewski; Jose Silva-Cardoso; Valentina Carubelli; Salvatore Di Somma; Heli Tolppanen; Uwe Zeymer; Holger Thiele; Markku S Nieminen; Alexandre Mebazaa Journal: Eur J Heart Fail Date: 2015-03-28 Impact factor: 15.534
Authors: George A Alba; Quynh A Truong; Hanna K Gaggin; Parul U Gandhi; Benedetta De Berardinis; Laura Magrini; Ednan K Bajwa; Salvatore Di Somma; James L Januzzi Journal: Am J Med Date: 2015-07-11 Impact factor: 4.965
Authors: Markku S Nieminen; Dirk Brutsaert; Kenneth Dickstein; Helmut Drexler; Ferenc Follath; Veli-Pekka Harjola; Matthias Hochadel; Michel Komajda; Johan Lassus; Jose Luis Lopez-Sendon; Piotr Ponikowski; Luigi Tavazzi Journal: Eur Heart J Date: 2006-09-25 Impact factor: 29.983
Authors: Alexandre Mebazaa; Mihai Gheorghiade; Ileana L Piña; Veli-Pekka Harjola; Steven M Hollenberg; Ferenc Follath; Andrew Rhodes; Patrick Plaisance; Edmond Roland; Markku Nieminen; Michel Komajda; Alexander Parkhomenko; Josep Masip; Faiez Zannad; Gerasimos Filippatos Journal: Crit Care Med Date: 2008-01 Impact factor: 7.598
Authors: Azam Torabi; John G F Cleland; Nasrin K Khan; Puan H Loh; Andrew L Clark; Farqad Alamgir; John L Caplin; Alan S Rigby; Kevin Goode Journal: Eur Heart J Date: 2008-03-19 Impact factor: 29.983
Authors: William Frank Peacock; Charles Emerman; Maria R Costanzo; Deborah B Diercks; Margarita Lopatin; Gregg C Fonarow Journal: Congest Heart Fail Date: 2009 Nov-Dec
Authors: M Heringlake; B Bein; M Buerke; D Damjanovic; H Ebelt; H V Groesdonk; A Markewitz; M Möckel; R Moosdorf; K Pilarczyk; D A Reuter; M Sander; A Schmitt; G Trummer; S Treskatsch; M Von der Brelie; B Zante; A Zarbock; N Haake Journal: Intensive Care Med Date: 2016-01-11 Impact factor: 17.440
Authors: Corstiaan A den Uil; Giorgia Galli; Lucia S Jewbali; Kadir Caliskan; Olivier C Manintveld; Jasper J Brugts; Nicolas M van Mieghem; Mattie J Lenzen; Eric Boersma; Alina A Constantinescu Journal: Cardiology Date: 2017-05-13 Impact factor: 1.869
Authors: S Tenzer; B Peters; S Bulik; O Schoor; C Lemmel; M M Schatz; P-M Kloetzel; H-G Rammensee; H Schild; H-G Holzhütter Journal: Cell Mol Life Sci Date: 2005-05 Impact factor: 9.261
Authors: Bernhard Wernly; Clemens Seelmaier; David Leistner; Barbara E Stähli; Ingrid Pretsch; Michael Lichtenauer; Christian Jung; Uta C Hoppe; Ulf Landmesser; Holger Thiele; Alexander Lauten Journal: Clin Res Cardiol Date: 2019-03-21 Impact factor: 5.460